Fulgent Genetics, Inc. is a technology-based genetic company with a laboratory services business and a therapeutic development business. The Company’s laboratory services business includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile (PK) profile of new and existing cancer drugs. Its technology platform for its laboratory services business includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. The platform provides a test menu, the ability to rapidly develop and launch new tests and customizable test offerings. The Company also offers next-generation sequencing (NGS) services.
Ticker SymbolFLGT
Company nameFulgent Genetics Inc
IPO dateSep 28, 2016
CEOMr. Ming Hsieh
Number of employees1313
Security typeOrdinary Share
Fiscal year-endSep 28
Address4399 Santa Anita Ave
CityEL MONTE
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code91731
Phone16263500537
Websitehttps://www.fulgentgenetics.com/
Ticker SymbolFLGT
IPO dateSep 28, 2016
CEOMr. Ming Hsieh
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data